本文選題：派杰氏病 + 人表皮生長因子受體�。� 參考：《中國癌癥雜志》2017年08期

【摘要】：背景與目的:乳房派杰氏病(Paget’s disease)是一種很罕見的疾病。文獻報道該病患者的生存情況與其下乳房內(nèi)的病灶的惡性程度相關(guān)。該研究旨在探索合并浸潤性乳腺癌的乳房派杰氏病的臨床病理特征并分析患者的生存率。方法:2002—2007年,共54例在復旦大學附屬腫瘤醫(yī)院接受治療的合并浸潤性乳腺癌的乳房派杰氏病患者納入該研究。由于乳腺派杰氏病大多數(shù)為人表皮生長因子受體2(human epidermal growth factor receptor 2,HER-2)陽性,研究者隨機收集了同期72例HER-2陽性浸潤性乳腺癌患者作為對照組,比較兩組的生存差異。結(jié)果:25例(46.3%)研究組患者沒有典型的乳頭乳暈派杰氏病皮膚表現(xiàn),35例(64.8%)研究組患者浸潤性癌灶超過2 cm,26例(48.1%)研究組患者腋窩淋巴結(jié)有轉(zhuǎn)移。與對照組的患者相比,派杰氏病患者的復發(fā)事件更多(5年無復發(fā)生存率:76.4%vs 48.5%,P0.01)。對照組復發(fā)事件多集中于術(shù)后3年內(nèi),而派杰氏患者復發(fā)風險在術(shù)后5年內(nèi)持續(xù)存在。研究組的5年總生存率(61.0%)也低于對照組(80.6%,P=0.01)。結(jié)論:合并浸潤性癌的乳房派杰氏病患者比HER-2陽性乳腺癌患者的預后差。
[Abstract]:Background & objective: Pagettasis disease of breast is a rare disease. It is reported that the survival of the patients is related to the malignancy of the lesions in the lower breast. The aim of this study was to investigate the clinicopathological features of breast Paget's disease with invasive breast cancer and to analyze the survival rate. Methods from 2002 to 2007, 54 patients with Paget's disease of breast with invasive breast cancer received treatment at the Cancer Hospital affiliated to Fudan University were included in the study. As the majority of human epidermal growth factor receptor (2(human epidermal growth factor receptor 2) HER-2) positive in Paget's disease, the researchers randomly collected 72 HER-2 positive invasive breast cancer patients as the control group, and compared the survival of the two groups. Results there were no typical skin manifestations of papillary areola Paget's disease in the study group (25 cases 46.3%). 35 cases of Paget's disease with papillary areola were found in the study group. There were 26 cases of invasive carcinoma more than 2 cm in the study group and 26 cases had metastasis of axillary lymph nodes in the study group. Compared with the control group, Paget's disease patients had more recurrent events (5-year recurrence free survival rate: 76.4 vs 48.5 / P0.01g / kg). The recurrence events in the control group were mainly within 3 years after operation, while the recurrence risk of Paget patients persisted within 5 years after operation. The 5-year overall survival rate in the study group was also lower than that in the control group. Conclusion: the prognosis of Paget's disease with invasive carcinoma is worse than that of HER-2 positive breast cancer.
【作者單位】： 復旦大學附屬腫瘤醫(yī)院乳腺外科復旦大學上海醫(yī)學院腫瘤學系;復旦大學附屬腫瘤醫(yī)院病理科復旦大學上海醫(yī)學院腫瘤學系;
【分類號】：R737.9

【相似文獻】

相關(guān)期刊論文 前10條

1 賀占青,王立平,吳軍,王鳳安,閆慶輝;乳腺浸潤性導管癌合并派杰氏病1例[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2002年14期

2 湯鵬;鐘曉捷;李冠喬;;乳房外派杰氏病一例[J];海南醫(yī)學;2011年24期

3 顧寶清,高志清;乳房派杰氏病[J];陜西新醫(yī)藥;1986年01期

4 陳常召;王春英;王志慧;;乳房派杰氏病(附14例臨床病理分析)[J];臨沂醫(yī)專學報;1992年01期

5 唐兆瑞;卜燕燕;;外陰浸潤性派杰氏病1例報告[J];中國社區(qū)醫(yī)師(醫(yī)學專業(yè));2010年01期

6 吳澄,任思珍;乳房派杰氏病1例報告[J];廠礦醫(yī)藥衛(wèi)生;1997年01期

7 崔永旺,李力軍,張士東,張駿;男性乳房派杰氏病二例[J];中華腫瘤雜志;1998年06期

8 常紹岳，，金國祥，劉兵;肛門周圍皮膚派杰氏病的診斷與治療（附3例報告）[J];山西醫(yī)藥雜志;1996年03期

9 劉寧,王成峰,邵永孚;乳腺癌合并派杰氏病34例分析[J];中華腫瘤雜志;2000年01期

10 袁鳳英，王保勤, 冀春萱;男性乳房外派杰氏病1例診治報告[J];山西醫(yī)學院學報;1995年02期

相關(guān)會議論文 前1條

1 吳秋萍;;乳房派杰氏病1例報告[A];2012年浙江省皮膚病性病學術(shù)會議論文集[C];2012年

本文編號：1995439